Goblet cell appendiceal tumors - Management dilemmas and long-term outcomes

Roberta Elisa Rossi, Tu Vinh Luong, Martyn Evan Caplin, Christina Thirlwell, Tim Meyer, Jorge Garcia-Hernandez, Alex Baneke, Dario Conte, Christos Toumpanakis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background Appendiceal Goblet cell tumors (GCTs) are clinically more aggressive, and have a worse outcome than midgut neuroendocrine tumors (mNETs). Guidelines for management of GCTs are limited. Methods A retrospective case-study analysis was performed in patients with a diagnosis of GCT, confirmed on histological review. Patients were evaluated clinically, biochemically, and radiologically. Results 48 patients were identified (TNM stage I-II: 27, stage III: 15, stage IV: 6). Median follow-up was 44 months and was complete in all patients. 68.8% presented with acute appendicitis. 44/48 patients had initial appendectomy, followed by prophylactic right hemicolectomy in 41. 10/48 patients had recurrent disease [median time to recurrence 28 months (range 4-159)]. Of those, 9 received systemic chemotherapy (FOLFOX/FOLFIRI), which was also given in 5/48 patients with disseminated disease at diagnosis. Partial response, stable disease and disease progression was noted in 22%, 22% and 56%, respectively. Adjuvant chemotherapy was also administered in 9/48 patients with stage III disease after right hemicolectomy, however in 3/9 the disease recurred. Median progression/disease-free-survival was 44 months (range 3-159) and overall 5-year survival rate was 41.6%. Conclusions The clinical behaviour of GCTs is more similar to colorectal adenocarcinomas than to NETs. A prophylactic right hemicolectomy is recommended to reduce the risk of recurrence. Systemic chemotherapy, using colorectal adenocarcinoma regimens, is indicated for advanced or recurrent disease and has encouraging results. Prospective studies are needed to define the role of adjuvant chemotherapy and the optimal chemotherapy regimen.

Original languageEnglish
Article number825
Pages (from-to)47-53
Number of pages7
JournalSurgical Oncology
Volume24
Issue number1
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Goblet Cells
Neoplasms
Adjuvant Chemotherapy
Drug Therapy
Disease-Free Survival
Adenocarcinoma
Recurrence
Appendectomy
Neuroendocrine Tumors
Appendicitis
Disease Progression
Survival Rate
Retrospective Studies
Prospective Studies
Guidelines

Keywords

  • Appendix
  • Chemotherapy
  • Goblet cell tumor
  • Right hemicolectomy

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Medicine(all)

Cite this

Rossi, R. E., Luong, T. V., Caplin, M. E., Thirlwell, C., Meyer, T., Garcia-Hernandez, J., ... Toumpanakis, C. (2015). Goblet cell appendiceal tumors - Management dilemmas and long-term outcomes. Surgical Oncology, 24(1), 47-53. [825]. https://doi.org/10.1016/j.suronc.2015.01.001

Goblet cell appendiceal tumors - Management dilemmas and long-term outcomes. / Rossi, Roberta Elisa; Luong, Tu Vinh; Caplin, Martyn Evan; Thirlwell, Christina; Meyer, Tim; Garcia-Hernandez, Jorge; Baneke, Alex; Conte, Dario; Toumpanakis, Christos.

In: Surgical Oncology, Vol. 24, No. 1, 825, 01.03.2015, p. 47-53.

Research output: Contribution to journalArticle

Rossi, RE, Luong, TV, Caplin, ME, Thirlwell, C, Meyer, T, Garcia-Hernandez, J, Baneke, A, Conte, D & Toumpanakis, C 2015, 'Goblet cell appendiceal tumors - Management dilemmas and long-term outcomes', Surgical Oncology, vol. 24, no. 1, 825, pp. 47-53. https://doi.org/10.1016/j.suronc.2015.01.001
Rossi RE, Luong TV, Caplin ME, Thirlwell C, Meyer T, Garcia-Hernandez J et al. Goblet cell appendiceal tumors - Management dilemmas and long-term outcomes. Surgical Oncology. 2015 Mar 1;24(1):47-53. 825. https://doi.org/10.1016/j.suronc.2015.01.001
Rossi, Roberta Elisa ; Luong, Tu Vinh ; Caplin, Martyn Evan ; Thirlwell, Christina ; Meyer, Tim ; Garcia-Hernandez, Jorge ; Baneke, Alex ; Conte, Dario ; Toumpanakis, Christos. / Goblet cell appendiceal tumors - Management dilemmas and long-term outcomes. In: Surgical Oncology. 2015 ; Vol. 24, No. 1. pp. 47-53.
@article{635052ae4dec4de6aaaf92c8dc916acd,
title = "Goblet cell appendiceal tumors - Management dilemmas and long-term outcomes",
abstract = "Background Appendiceal Goblet cell tumors (GCTs) are clinically more aggressive, and have a worse outcome than midgut neuroendocrine tumors (mNETs). Guidelines for management of GCTs are limited. Methods A retrospective case-study analysis was performed in patients with a diagnosis of GCT, confirmed on histological review. Patients were evaluated clinically, biochemically, and radiologically. Results 48 patients were identified (TNM stage I-II: 27, stage III: 15, stage IV: 6). Median follow-up was 44 months and was complete in all patients. 68.8{\%} presented with acute appendicitis. 44/48 patients had initial appendectomy, followed by prophylactic right hemicolectomy in 41. 10/48 patients had recurrent disease [median time to recurrence 28 months (range 4-159)]. Of those, 9 received systemic chemotherapy (FOLFOX/FOLFIRI), which was also given in 5/48 patients with disseminated disease at diagnosis. Partial response, stable disease and disease progression was noted in 22{\%}, 22{\%} and 56{\%}, respectively. Adjuvant chemotherapy was also administered in 9/48 patients with stage III disease after right hemicolectomy, however in 3/9 the disease recurred. Median progression/disease-free-survival was 44 months (range 3-159) and overall 5-year survival rate was 41.6{\%}. Conclusions The clinical behaviour of GCTs is more similar to colorectal adenocarcinomas than to NETs. A prophylactic right hemicolectomy is recommended to reduce the risk of recurrence. Systemic chemotherapy, using colorectal adenocarcinoma regimens, is indicated for advanced or recurrent disease and has encouraging results. Prospective studies are needed to define the role of adjuvant chemotherapy and the optimal chemotherapy regimen.",
keywords = "Appendix, Chemotherapy, Goblet cell tumor, Right hemicolectomy",
author = "Rossi, {Roberta Elisa} and Luong, {Tu Vinh} and Caplin, {Martyn Evan} and Christina Thirlwell and Tim Meyer and Jorge Garcia-Hernandez and Alex Baneke and Dario Conte and Christos Toumpanakis",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.suronc.2015.01.001",
language = "English",
volume = "24",
pages = "47--53",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Goblet cell appendiceal tumors - Management dilemmas and long-term outcomes

AU - Rossi, Roberta Elisa

AU - Luong, Tu Vinh

AU - Caplin, Martyn Evan

AU - Thirlwell, Christina

AU - Meyer, Tim

AU - Garcia-Hernandez, Jorge

AU - Baneke, Alex

AU - Conte, Dario

AU - Toumpanakis, Christos

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background Appendiceal Goblet cell tumors (GCTs) are clinically more aggressive, and have a worse outcome than midgut neuroendocrine tumors (mNETs). Guidelines for management of GCTs are limited. Methods A retrospective case-study analysis was performed in patients with a diagnosis of GCT, confirmed on histological review. Patients were evaluated clinically, biochemically, and radiologically. Results 48 patients were identified (TNM stage I-II: 27, stage III: 15, stage IV: 6). Median follow-up was 44 months and was complete in all patients. 68.8% presented with acute appendicitis. 44/48 patients had initial appendectomy, followed by prophylactic right hemicolectomy in 41. 10/48 patients had recurrent disease [median time to recurrence 28 months (range 4-159)]. Of those, 9 received systemic chemotherapy (FOLFOX/FOLFIRI), which was also given in 5/48 patients with disseminated disease at diagnosis. Partial response, stable disease and disease progression was noted in 22%, 22% and 56%, respectively. Adjuvant chemotherapy was also administered in 9/48 patients with stage III disease after right hemicolectomy, however in 3/9 the disease recurred. Median progression/disease-free-survival was 44 months (range 3-159) and overall 5-year survival rate was 41.6%. Conclusions The clinical behaviour of GCTs is more similar to colorectal adenocarcinomas than to NETs. A prophylactic right hemicolectomy is recommended to reduce the risk of recurrence. Systemic chemotherapy, using colorectal adenocarcinoma regimens, is indicated for advanced or recurrent disease and has encouraging results. Prospective studies are needed to define the role of adjuvant chemotherapy and the optimal chemotherapy regimen.

AB - Background Appendiceal Goblet cell tumors (GCTs) are clinically more aggressive, and have a worse outcome than midgut neuroendocrine tumors (mNETs). Guidelines for management of GCTs are limited. Methods A retrospective case-study analysis was performed in patients with a diagnosis of GCT, confirmed on histological review. Patients were evaluated clinically, biochemically, and radiologically. Results 48 patients were identified (TNM stage I-II: 27, stage III: 15, stage IV: 6). Median follow-up was 44 months and was complete in all patients. 68.8% presented with acute appendicitis. 44/48 patients had initial appendectomy, followed by prophylactic right hemicolectomy in 41. 10/48 patients had recurrent disease [median time to recurrence 28 months (range 4-159)]. Of those, 9 received systemic chemotherapy (FOLFOX/FOLFIRI), which was also given in 5/48 patients with disseminated disease at diagnosis. Partial response, stable disease and disease progression was noted in 22%, 22% and 56%, respectively. Adjuvant chemotherapy was also administered in 9/48 patients with stage III disease after right hemicolectomy, however in 3/9 the disease recurred. Median progression/disease-free-survival was 44 months (range 3-159) and overall 5-year survival rate was 41.6%. Conclusions The clinical behaviour of GCTs is more similar to colorectal adenocarcinomas than to NETs. A prophylactic right hemicolectomy is recommended to reduce the risk of recurrence. Systemic chemotherapy, using colorectal adenocarcinoma regimens, is indicated for advanced or recurrent disease and has encouraging results. Prospective studies are needed to define the role of adjuvant chemotherapy and the optimal chemotherapy regimen.

KW - Appendix

KW - Chemotherapy

KW - Goblet cell tumor

KW - Right hemicolectomy

UR - http://www.scopus.com/inward/record.url?scp=84925937660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925937660&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2015.01.001

DO - 10.1016/j.suronc.2015.01.001

M3 - Article

C2 - 25686643

AN - SCOPUS:84925937660

VL - 24

SP - 47

EP - 53

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 1

M1 - 825

ER -